Bispecific Antibodies

  • Discovery of bispecific antibodies with two innovative targets that may improve antibody therapy of cancer and autoimmune diseases.
  • Base on the Biocytogen’s High-throughput mAb platform, we can supply unique mAb sequence for bispecific antibody development.
  • Any IgG mAb sequence can be customized to bispecific antibody, include different valency (2,3 or 4 binding sites), both asymmetric and symmetric formats.
  • In vitro and in vivo experiments designed to support the MOA of bispecific antibody.
Back to top